The combination treatment of PD-1 Nb20 with the tumor-specific DC/tumor-fusion cell (FC) vaccine was observed to effectively improve the in vitro cytotoxicity of CD8+ T cells to kill HCC HepG2 cells. The gene discussed is CD8A; the disease is neoplasm.